Abstract
Context: Myeloma bone disease (MBD) is a devastating complication of multiple myeloma that leads to severe pain. Objectives: The aim of this study was to evaluate the efficacy and tolerability of tapentadol prolonged release (PR) in the management of patients with MBD suffering from moderate-to-severe cancer pain. Methods: A 12-week prospective study was carried out in 25 opioid-naïve MBD patients. Patients initially received twice-daily doses of tapentadol PR 50 mg. Doses were then managed to maintain adequate relief or dose-limiting toxicity. The following parameters were recorded at weekly intervals for 4 weeks, and then at weeks 8 and 12: pain, opioid-related adverse effects, use of other analgesics, DN4 (Douleur Neuropathique 4) score. Quality of life (SF-36 [36-item short-form health survey]) was measured at baseline and at final evaluation. Results: Of 25 patients, 22 completed the study. Pain intensity significantly decreased from baseline to all the week intervals (P
Original language | English (US) |
---|---|
Pages (from-to) | 229-238 |
Number of pages | 10 |
Journal | Journal of Pain Research |
Volume | 8 |
DOIs | |
State | Published - May 8 2015 |
Keywords
- Bone
- Multiple myeloma
- Neuropathic pain
- Opioids
- Tapentadol
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine